First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Karyopharm Therapeutics: the story is balanced — Clinical trial data readouts for XPOVIO combination studies in multiple myeloma and potential new indications…
★ Analysts see FY2027 revenue reaching $155M — +13.2% growth in a single year.
What Moves the Stock
1Clinical trial data readouts for XPOVIO combination studies in multiple myeloma and potential new indications (endometrial cancer, myelofibrosis)
2Quarterly XPOVIO prescription trends and market share data in multiple myeloma versus competing regimens (Darzalex combinations, CAR-T therapies, bispecifics)
3Partnership or licensing deal announcements for ex-US territories or combination development programs
4Cash runway updates and financing announcements given negative operating cash flow of $100M+ annually
5FDA regulatory decisions on label expansion applications or new indication submissions
6XPOVIO (selinexor) US commercial sales for relapsed/refractory multiple myeloma (~70-80% of revenue estimate)
7XPOVIO US sales for relapsed/refractory diffuse large B-cell lymphoma (~15-20% of revenue estimate)
8International licensing revenue and milestone payments (~5-10% of revenue estimate)
momentum - The stock attracts speculative biotech traders focused on binary clinical catalysts and partnership rumors rather…
Rising interest rates negatively impact valuation multiples for unprofitable biotech companies as the present value of distant future cash…
Watch on earnings: Weekly XPOVIO prescription data from Symphony Health or IQVIA tracking market penetration trends, Cash and marketable securities balance versus quarterly burn rate to assess financing urgency, Phase 3 SIENDO trial interim analysis timing for endometrial cancer indication (primary growth catalyst).
One Sentence Summary:
Karyopharm Therapeutics: the story is balanced — clinical trial data readouts for xpovio combination studies in multiple myeloma and potential new indications (endometrial cancer.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.